{
  "source": "PA-Notification-Palforzia.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1324-7\nProgram Prior Authorization – Notification\nMedication Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp]\nP&T Approval Date 8/2020, 8/2021, 3/2022, 3/2023, 3/2024, 3/2025, 4/2025\nEffective Date 7/1/2025\n1. Background:\nPalforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] is an oral immunotherapy\nindicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with\naccidental exposure to peanuts. Palforzia is approved for use in patients with a confirmed\ndiagnosis of peanut allergy. Initial dose escalation may be administered to patients aged 1\nthrough 17 years. Up-dosing and maintenance may be continued in patients 1 year of age and\nolder. Palforzia is to be used in conjunction with a peanut-avoidant diet.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Palforzia will be approved based on the following criteria:\na. Diagnosis of peanut allergy as documented by both of the following:\n(1) A serum peanut-specific IgE level of greater than or equal to 0.35 kUA/L\n(2) A mean wheal diameter that is at least 3mm larger than the negative control on skin-\nprick testing for peanut\n- AND -\nb. One of the following\n(1) Both of the following\n(a) Patient is 1 to 17 years of age\n(b) Patient is in the initial dose escalation phase therapy\n-OR-\n(2) Both of the following:\n(a) Patient is 1 year of age and older\n(b) Patient is in the up-dosing or maintenance phase of therapy\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n1\nc. Used in conjunction with a peanut-avoidant diet\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Palforzia will be approved based on the following criteria:\na. Documentation of positive clinical response to Palforzia therapy\n-AND-\nb. Used in conjunction with a peanut-avoidant diet\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage ",
    "ed in conjunction with a peanut-avoidant diet\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Prior Authorization-Medical Necessity may apply\n• Supply limits may apply\n4. References:\n1. The PALISADE Group of Clinical Investigators. AR101 Oral Immunotherapy for Peanut Allergy.\nN Engl J Med. 379(21):1991-2001.\n2. Palforzia [prescribing information]. Bridgewater, NJ: Aimmune Therapeutics, Inc.; July 2024.\nProgram Prior Authorization – Notification – Palforzia\nChange Control\n8/2020 New program.\n8/2021 Annual review. No changes.\n3/2022 No changes.\n3/2023 Annual review. Added mandate language.\n3/2024 Annual review. Updated references.\n3/2025 Annual review. No changes.\n4/2025 Updated age range based on update to prescribing information.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}